Publications                                                                                                                               
Burdock, GA and Carabin, IG (2008) Breaking Down the Barriers to Functional Foods,
Nutraceuticals and Claims. Book Chapter In: Nutraceutical and Functional Food Regulation
in the United States and Around the World, a volume of the Food Science and Technology,
International Series. Elsevier, Inc., NY, p. 83-108.

Carabin, IG and Griffiths, JC (2007). Functional Foods & Structure/Function Claims. Is There a Difference Between Sexes? Nutritional Outlook, June issue.

Carabin, IG (2006). Functional foods for women’s health.  Natural Products Industry
Insider, August.

Carabin, IG and Casterton, P. (2006). Allergen labeling. Protecting the public. Asia Food Journal. May 2006.

Carabin, IG and Matulka, R. (2006). Proving efficacy. The World of Food Ingredients. April/May.

Carabin, IG and Magnuson, BA (2006). New Labeling Requirements for Food Allergens. Nutritional Outlook, April.

Burdock, GA, Carabin, IG and Griffiths, JC (2006). The Importance of GRAS to the Functional Foods and Nutraceutical Industries. Toxicology 221, p. 17-27.

Carabin, IG (2005). The Clinical Aspects of Claim Substantiation: The Concept of Cause and Effect. FDLI Update, Issue 2, p. 36-39.

Carabin, IG and Burdock, GA (2005). Obesity in the United States: An overview. FDLI Update, Issue 1, p. 9-14.

Carabin, IG (2004). The Role of Clinical Trials in Dietary Supplement Claim Substantiation. A Regulatory and Historical Perspective. ACRP Monitor, Vol. 18, Issue 4, p. 25-29.

Carabin, IG (2004). The Clinical Aspects of Claim Substantiation: Inclusion/Exclusion Criteria, Screening and Baseline Evaluations in Clinical Trials. FDLI Update, Issue 5, p. 41-45.

Carabin, IG (2004). The Clinical Aspects of Claim Substantiation: Clinical Trial Costs. FDLI Update, Issue 4, p. 39-43.

Carabin, IG (2004). The Clinical Aspects of Claim Substantiation. FDLI Update, Issue 3, p. 25-29.

Burdock, GA and Carabin, IG (2004). Warning Letters, Recalls and the “Elixir of Death.” FDA Regulation in Nutritional Outlook, March.

Burdock, GA and Carabin, IG (2004). Generally Recognized As Safe (GRAS): History and Description. Toxicol Lett. Apr15: 150(1): 3-18.